Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and ASC36_35FDC Once-Monthly Injection, a Co-Formulation...
-ASC36_35FDC, a once-monthly subcutaneous (SQ) fixed dose combination (FDC) injection of ASC36 and ASC35, is a potentially first-in-class drug candidate which targets three validated targets of amylin receptor, GLP-1R and GIPR. -ASC36 is a potentially first-in-class once-monthly to once-quarterly SQ injection which targets amylin receptor. -Investigational New Drug (IND) Applications for...
Dx&Vx Signs Two Material Transfer Agreements in Latin America Within Two Months — “Technology Validated Across Both Public and Private Sectors”
— Argentine biopharmaceutical company in July, South American public health institution in August sign consecutive KRNA material transfer agreements— Two of five cumulative MTAs now in Latin America, as company accelerates entry into the region's pharmaceutical market SEOUL, South Korea, Aug. 10, 2026 /PRNewswire/ -- Dx&Vx (DXVX, KRX: 180400), a biopharmaceutical...
New ReSound Sensia™ hearing aids lift the voice you want to hear – not just the loudest
Automatically, accurately, proven. BALLERUP, Denmark, Aug. 10, 2026 /PRNewswire/ -- GN, a global leader in hearing technology, announces ReSound Sensia™, a new family of premium hearing aids built on the company's new AI platform. ReSound Sensia combines the world's most accurate environmental classifier, an advanced 4-microphone directional beamformer and Deep Neural Network...
Akeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer
HONG KONG, Aug. 10, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase II clinical study (AK146D1-202) evaluating AK146D1, the Company's internally developed TROP2/Nectin-4 bispecific antibody-drug conjugate (bsADC), in combination with ivonescimab (the Company's PD-1/VEGF bispecific antibody), for the treatment of advanced breast cancer. This study aims...
Chinese and Indonesian cardiologists complete Southeast Asia’s first “noise-free” cardiac procedure in Jakarta
JAKARTA, Indonesia, Aug. 10, 2026 /PRNewswire/ -- Cardiologists from China and Indonesia have successfully completed Southeast Asia's first complex Chronic Total Occlusion (CTO) procedure guided by United Imaging's uAngio AVIVA angiography system. The procedure, performed recently, was broadcast live to over 500 interventional cardiologists across the region as a hands-on demonstration for the Advanced CTO Masterclass 2026, co-hosted...
2026 Global Health Summit Opens in Hong Kong — Global Healthcare Leaders Convene: Bringing Breakthroughs to Patients
HONG KONG, Aug. 10, 2026 /PRNewswire/ -- The 2026 Global Health Summit ("GHS 2026"), jointly hosted by New Frontier Group ("New Frontier") and the Hong Kong Investment Corporation Limited ("HKIC"), opened today at the Hong Kong Convention and Exhibition Centre for a two-day programme. Held under the theme "EXPONENTIAL: From Breakthrough Discoveries to Global Impact," the Summit convened...
Second PIC/S GMP Certification | Mabwell Passes Brazilian GMP Inspection for Its Denosumab Injections
SHANGHAI, Aug. 10, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announces that its wholly-owned subsidiary T-mab has successfully passed Brazilian Health Regulatory Agency's ("ANVISA") GMP on-site inspection for its denosumab biosimilars, 9MW0311 (Prolia® biosimilar) and 9MW0321 (Xgeva® biosimilar). This is Mabwell's second GMP certification from a Pharmaceutical Inspection Co-operation...
RiboX Therapeutics Announces FDA IND Clearance for RXIM002, the first Circular RNA-Based in vivo CAR Therapy for Autoimmune Cytopenias
The FDA IND clearance supports the initiation of RiboX's Phase 1 clinical trial evaluating targeted LNP-delivered circular RNA-based in vivo CAR-T therapy for autoimmune cytopenias. RXIM002 represents the world's first circular RNA-based in vivo CAR-T therapy achieving FDA IND clearance. RiboX expands its clinical-stage pipeline through its proprietary targeted LNP delivery platform. SHANGHAI and CAMBRIDGE, Mass., Aug. 8,...
RiboX Therapeutics Announces FDA IND Clearance for RXIM002, the first Circular RNA-Based in vivo CAR Therapy for Autoimmune Cytopenias
The FDA IND clearance supports the initiation of RiboX's Phase 1 clinical trial evaluating targeted LNP-delivered circular RNA-based in vivo CAR-T therapy for autoimmune cytopenias. RXIM002 represents the world's first circular RNA-based in vivo CAR-T therapy achieving FDA IND clearance. RiboX expands its clinical-stage pipeline through its proprietary targeted LNP delivery platform. SHANGHAI and CAMBRIDGE, Mass., Aug. 8,...
RiboX Therapeutics Announces FDA IND Clearance for RXIM002, the first Circular RNA-Based in vivo CAR Therapy for Autoimmune Cytopenias
The FDA IND clearance supports the initiation of RiboX's Phase 1 clinical trial evaluating targeted LNP-delivered circular RNA-based in vivo CAR-T therapy for autoimmune cytopenias. RXIM002 represents the world's first circular RNA-based in vivo CAR-T therapy achieving FDA IND clearance. RiboX expands its clinical-stage pipeline through its proprietary targeted LNP delivery platform. SHANGHAI and CAMBRIDGE, Mass., Aug. 8,...
